Literature DB >> 2856876

Characterization of spontaneous colitis in cotton-top tamarins (Saguinus oedipus) and its response to sulfasalazine.

J L Madara, D K Podolsky, N W King, P K Sehgal, R Moore, H S Winter.   

Abstract

Chronic colitis in the cotton-top tamarin (CTT) has been characterized by obtaining distal colonic biopsy specimens, hematocrits, serum albumins, and stools for bacteriologic and parasitic examination in nondebilitated living CTTs. The species specificity of the histologic features of colitis observed in the CTT was assessed by obtaining distal colonic biopsy specimens from 10 animals of other primate species for histologic examination. Histologic evidence of active colitis was found in 50% of adult CTTs but was absent in all non-CTT species studied. Forty-two stool samples obtained from 18 CTTs yielded only one isolate (Campylobacter). In addition to active colitis, CTT rectal mucosa also often had subtle irregularities in mucosal structure that were not present in nonrelated primate species and might represent chronic colitis. Metaplasia was not observed. The therapeutic effects of oral sulfasalazine (50 mg/kg X day) on CTT colitis were assessed in a randomized 10-wk placebo controlled crossover study. This study demonstrated significant improvement in disease activity as judged histologically (p less than 0.05) and significant increases in animal weight (p less than 0.01) and serum albumin (p less than 0.01) during sulfasalazine therapy when compared with saline control. Sulfasalazine therapy can ameliorate the effects of this disease and offers promise in maintaining experimental colonies of this endangered species for future studies.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2856876     DOI: 10.1016/s0016-5085(85)80126-8

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  17 in total

Review 1.  Current concept of pathophysiological understanding and natural course of ulcerative colitis.

Authors:  Martin H Holtmann; Peter R Galle
Journal:  Langenbecks Arch Surg       Date:  2004-02-04       Impact factor: 3.445

2.  Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha.

Authors:  P E Watkins; B F Warren; S Stephens; P Ward; R Foulkes
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

Review 3.  Leukocyte adhesion molecules in animal models of inflammatory bowel disease.

Authors:  Jesús Rivera-Nieves; Gezahegn Gorfu; Klaus Ley
Journal:  Inflamm Bowel Dis       Date:  2008-12       Impact factor: 5.325

Review 4.  Neutrophil autoantibodies as disease markers for ulcerative colitis.

Authors:  F Shanahan; C Landers; R Duerr; S R Targan
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

5.  Inflammatory mediators in cotton-top tamarins (CTT) with acute and chronic colitis.

Authors:  N K Clapp; M A Henke; R M Hansard; R E Walsh; D L Widomski; C P Anglin; D J Fretland; T S Gaginella
Journal:  Agents Actions       Date:  1991-09

6.  Nonviral infectious agents and marmoset (Saguinus oedipus) colitis.

Authors:  R Moore
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

7.  Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody.

Authors:  D K Podolsky; R Lobb; N King; C D Benjamin; B Pepinsky; P Sehgal; M deBeaumont
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

8.  The characterization of a rabbit model of inflammatory bowel disease.

Authors:  D Anthony; F Savage; V Sams; P Boulos
Journal:  Int J Exp Pathol       Date:  1995-06       Impact factor: 1.925

9.  Acute colitis produced by chemotactic peptides in rats and mice.

Authors:  J F Chester; J S Ross; R A Malt; S A Weitzman
Journal:  Am J Pathol       Date:  1985-11       Impact factor: 4.307

10.  Differences in cellular glycoconjugates of quiescent, inflamed, and neoplastic colonic epithelium in colitis and cancer-prone tamarins.

Authors:  R Moore; N King; J Alroy
Journal:  Am J Pathol       Date:  1988-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.